What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study

BACKGROUND: Neoadjuvant therapy with dual HER2 blockade improved pathological complete response (pCR) rate in HER2‐positive breast cancer patients. Nevertheless, it would be desirable to identify patients exquisitely responsive to single agent trastuzumab to minimize or avoid overtreatment. Herein,...

Descripción completa

Detalles Bibliográficos
Autores principales: Pizzamiglio, Sara, Cosentino, Giulia, Ciniselli, Chiara M., De Cecco, Loris, Cataldo, Alessandra, Plantamura, Ilaria, Triulzi, Tiziana, El‐abed, Sarra, Wang, Yingbo, Bajji, Mohammed, Nuciforo, Paolo, Huober, Jens, Ellard, Susan L., Rimm, David L., Gombos, Andrea, Daidone, Maria Grazia, Verderio, Paolo, Tagliabue, Elda, Di Cosimo, Serena, Iorio, Marilena V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729061/
https://www.ncbi.nlm.nih.gov/pubmed/34921525
http://dx.doi.org/10.1002/cam4.4449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729061/
https://www.ncbi.nlm.nih.gov/pubmed/34921525
http://dx.doi.org/10.1002/cam4.4449

Ejemplares similares